Compare CRGO & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRGO | GALT |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.4M | 232.3M |
| IPO Year | N/A | N/A |
| Metric | CRGO | GALT |
|---|---|---|
| Price | $2.32 | $4.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 72.5K | ★ 794.2K |
| Earning Date | 11-17-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,642,000.00 | N/A |
| Revenue This Year | $26.59 | N/A |
| Revenue Next Year | $23.43 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.55 | N/A |
| 52 Week Low | $1.72 | $0.84 |
| 52 Week High | $4.42 | $7.13 |
| Indicator | CRGO | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 25.25 | 33.90 |
| Support Level | $2.27 | $3.53 |
| Resistance Level | $2.72 | $7.13 |
| Average True Range (ATR) | 0.16 | 0.63 |
| MACD | -0.06 | -0.27 |
| Stochastic Oscillator | 8.42 | 12.78 |
Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters. forwarders, and dozens of airlines and ocean carriers. WebCargo by Freightos is a freight platform connecting carriers and forwarders in particular an air cargo eBooking platform. Freightos.com is a digital international freight marketplace for importers and exporters for instant pricing, booking, and shipment management. The company operates in two segments-Platform segment and Solutions segment. Geographically, the company operates in Europe, Hong Kong, United States which is majority revenue generator and others.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.